nach oben

Erschienen in:

19.03.2016 | Article

The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants

verfasst von: Farah A. Meah, Linda A. DiMeglio, Carla J. Greenbaum, Janice S. Blum, Jay M. Sosenko, Alberto Pugliese, Susan Geyer, Ping Xu, Carmella Evans-Molina, for the Type 1 Diabetes TrialNet Study Group

Erschienen in: Diabetologia | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

The incidence of type 1 diabetes is increasing at a rate of 3–5% per year. Genetics cannot fully account for this trend, suggesting an influence of environmental factors. The accelerator hypothesis proposes an effect of metabolic factors on type 1 diabetes risk. To test this in the TrialNet Pathway to Prevention (PTP) cohort, we analysed the influence of BMI, weight status and insulin resistance on progression from single to multiple islet autoantibodies (Aab) and progression from normoglycaemia to diabetes.

Methods

HOMA1-IR was used to estimate insulin resistance in Aab-positive PTP participants. Cox proportional hazards models were used to evaluate the effects of BMI, BMI percentile (BMI%), weight status and HOMA1-IR on the progression of autoimmunity or the development of diabetes.

Results

Data from 1,310 single and 1,897 multiple Aab-positive PTP participants were included. We found no significant relationships between BMI, BMI%, weight status or HOMA1-IR and the progression from one to multiple Aabs. Similarly, among all Aab-positive participants, no significant relationships were found between BMI, weight status or HOMA1-IR and progression to diabetes. Diabetes risk was modestly increased with increasing BMI% among the entire cohort, in obese participants 13–20 years of age and with increasing HOMA1-IR in adult Aab-positive participants.

Conclusions/interpretation

Analysis of the accelerator hypothesis in the TrialNet PTP cohort does not suggest a broad influence of metabolic variables on diabetes risk. Efforts to identify other potentially modifiable environmental factors should continue.

Nur mit Berechtigung zugänglich

Onkamo P, Vaananen S, Karvonen M, Tuomilehto J (1999) Worldwide increase in incidence of Type I diabetes--the analysis of the data on published incidence trends. Diabetologia 42:1395–1403CrossRefPubMed

DIAMOND Project Group (2006) Incidence and trends of childhood type 1 diabetes worldwide 1990-1999. Diabet Med 23:857–866CrossRef

Patterson CC, Dahlquist GG, Gyurus E, Green A, Soltesz G (2009) Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 373:2027–2033CrossRefPubMed

Lawrence JM, Imperatore G, Dabelea D et al (2014) Trends in incidence of type 1 diabetes among non-hispanic white youth in the United States, 2002-2009. Diabetes 63:3938–3945CrossRefPubMedPubMedCentral

Donath MY, Hess C, Palmer E (2014) What is the role of autoimmunity in type 1 diabetes? A clinical perspective. Diabetologia 57:653–655CrossRefPubMed

Fourlanos S, Varney MD, Tait BD et al (2008) The rising incidence of type 1 diabetes is accounted for by cases with lower-risk human leukocyte antigen genotypes. Diabetes Care 31:1546–1549CrossRefPubMedPubMedCentral

Redondo MJ, Yu L, Hawa M et al (2001) Heterogeneity of type I diabetes: analysis of monozygotic twins in Great Britain and the United States. Diabetologia 44:354–362CrossRefPubMed

Bodansky HJ, Staines A, Stephenson C, Haigh D, Cartwright R (1992) Evidence for an environmental effect in the aetiology of insulin dependent diabetes in a transmigratory population. Br Med J (Clin Res Ed) 304:1020–1022CrossRef

Bach JF (2002) The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347:911–920CrossRefPubMed

10.

Schneider DA, von Herrath MG (2014) Potential viral pathogenic mechanism in human type 1 diabetes. Diabetologia 57:2009–2018CrossRefPubMedPubMedCentral

11.

Vaarala O, Atkinson MA, Neu J (2008) The “perfect storm” for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes 57:2555–2562CrossRefPubMedPubMedCentral

12.

Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM (2001) Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 358:1500–1503CrossRefPubMed

13.

Kimpimaki T, Kupila A, Hamalainen AM et al (2001) The first signs of beta-cell autoimmunity appear in infancy in genetically susceptible children from the general population: the Finnish Type 1 Diabetes Prediction and Prevention Study. J Clin Endocrinol Metab 86:4782–4788PubMed

14.

Howard SG, Lee DH (2012) What is the role of human contamination by environmental chemicals in the development of type 1 diabetes? J Epidemiol Community Health 66:479–481CrossRefPubMed

15.

Wilkin TJ (2008) Diabetes: 1 and 2, or one and the same? Progress with the accelerator hypothesis. Pediatr Diabetes 9:23–32CrossRefPubMed

16.

Johansson C, Samuelsson U, Ludvigsson J (1994) A high weight gain early in life is associated with an increased risk of type 1 (insulin-dependent) diabetes mellitus. Diabetologia 37:91–94CrossRefPubMed

17.

Knerr I, Wolf J, Reinehr T et al (2005) The ‘accelerator hypothesis’: relationship between weight, height, body mass index and age at diagnosis in a large cohort of 9,248 German and Austrian children with type 1 diabetes mellitus. Diabetologia 48:2501–2504CrossRefPubMed

18.

Dabelea D, D’Agostino RB Jr, Mayer-Davis EJ et al (2006) Testing the accelerator hypothesis: body size, beta-cell function, and age at onset of type 1 (autoimmune) diabetes. Diabetes Care 29:290–294CrossRefPubMed

19.

Kibirige M, Metcalf B, Renuka R, Wilkin TJ (2003) Testing the accelerator hypothesis: the relationship between body mass and age at diagnosis of type 1 diabetes. Diabetes Care 26:2865–2870CrossRefPubMed

20.

Fryar CD CM, Ogden CL (2012) Prevalence of Obesity Among Children and Adolescents: United States, Trends 1963–1965 Through 2009–2010. Available from http://www.cdc.gov/nchs/data/hestat/obesity_child_09_10/obesity_child_09_10.pdf, accessed 29 Mar 2014.

21.

Xu P, Cuthbertson D, Greenbaum C, Palmer JP, Krischer JP (2007) Role of insulin resistance in predicting progression to type 1 diabetes. Diabetes Care 30:2314–2320CrossRefPubMed

22.

Chase HP, Cuthbertson DD, Dolan LM et al (2001) First-phase insulin release during the intravenous glucose tolerance test as a risk factor for type 1 diabetes. J Pediatr 138:244–249CrossRefPubMed

23.

Sosenko JM, Skyler JS, Mahon J et al (2011) Validation of the Diabetes Prevention Trial-type 1 risk score in the TrialNet Natural History Study. Diabetes Care 34:1785–1787CrossRefPubMedPubMedCentral

24.

Sosenko JM, Skyler JS, Mahon J et al (2014) Use of the Diabetes Prevention Trial-type 1 risk score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes. Diabetes Care 37:979–984CrossRefPubMedPubMedCentral

25.

Sosenko JM, Skyler JS, Mahon J et al (2012) The application of the Diabetes Prevention Trial-type 1 risk score for identifying a preclinical state of type 1 diabetes. Diabetes Care 35:1552–1555CrossRefPubMedPubMedCentral

26.

Skyler JS, Greenbaum CJ, Lachin JM et al (2008) Type 1 Diabetes TrialNet--an international collaborative clinical trials network. Ann N Y Acad Sci 1150:14–24CrossRefPubMedPubMedCentral

27.

Mahon JL, Sosenko JM, Rafkin-Mervis L et al (2009) The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatr Diabetes 10:97–104CrossRefPubMed

28.

Yu L, Boulware DC, Beam CA et al (2012) Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies. Diabetes Care 35:1213–1218CrossRefPubMedPubMedCentral

29.

Greenbaum CJ, Mandrup-Poulsen T, McGee PF et al (2008) Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 31:1966–1971CrossRefPubMedPubMedCentral

30.

Vehik K, Beam CA, Mahon JL et al (2011) Development of autoantibodies in the TrialNet Natural History Study. Diabetes Care 34:1897–1901CrossRefPubMedPubMedCentral

31.

Sosenko JM, Mahon J, Rafkin L et al (2011) A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants. Pediatr Diabetes 12:85–90CrossRefPubMedPubMedCentral

32.

(2002) Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 346:1685–1691

33.

Ogden CL, Kuczmarski RJ, Flegal KM et al (2002) Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics 109:45–60CrossRefPubMed

34.

American Diabetes Association (2014) Standards of medical care in diabetes--2014. Diabetes Care 37(Suppl 1):S14–S80CrossRef

35.

Lin DY, Wei LJ, Ying Z (1993) Checking the Cox model with cumulative sums of Martingale-based residuals. Biometrika 80:557–572CrossRef

36.

Erlich H, Valdes AM, Noble J et al (2008) HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes 57:1084–1092CrossRefPubMedPubMedCentral

37.

Steck AK, Armstrong TK, Babu SR, Eisenbarth GS (2011) Stepwise or linear decrease in penetrance of type 1 diabetes with lower-risk HLA genotypes over the past 40 years. Diabetes 60:1045–1049CrossRefPubMedPubMedCentral

38.

Ogden CL, Carroll MD, Kit BK, Flegal KM (2014) Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 311:806–814CrossRefPubMedPubMedCentral

39.

(2000) Variation and trends in incidence of childhood diabetes in Europe. EURODIAB ACE Study Group. Lancet 355:873–876

40.

Winkler C, Marienfeld S, Zwilling M, Bonifacio E, Ziegler AG (2009) Is islet autoimmunity related to insulin sensitivity or body weight in children of parents with type 1 diabetes? Diabetologia 52:2072–2078CrossRefPubMed

41.

Lamb MM, Yin X, Zerbe GO et al (2009) Height growth velocity, islet autoimmunity and type 1 diabetes development: the Diabetes Autoimmunity Study in the Young. Diabetologia 52:2064–2071CrossRefPubMedPubMedCentral

42.

Cedillo M, Libman IM, Arena VC et al (2015) Obesity, islet cell autoimmunity, and cardiovascular risk factors in youth at onset of type 1 autoimmune diabetes. J Clin Endocrinol Metab 100:E82–E86CrossRefPubMedPubMedCentral

43.

Lipman TH, Levitt Katz LE, Ratcliffe SJ et al (2013) Increasing incidence of type 1 diabetes in youth: twenty years of the Philadelphia Pediatric Diabetes Registry. Diabetes Care 36:1597–1603CrossRefPubMedPubMedCentral

44.

Gimenez M, Aguilera E, Castell C, de Lara N, Nicolau J, Conget I (2007) Relationship between BMI and age at diagnosis of type 1 diabetes in a Mediterranean area in the period of 1990-2004. Diabetes Care 30:1593–1595CrossRefPubMed

45.

O’Connell MA, Donath S, Cameron FJ (2007) Major increase in type 1 diabetes: no support for the accelerator hypothesis. Diabet Med 24:920–923CrossRefPubMed

46.

Couper JJ, Beresford S, Hirte C et al (2009) Weight gain in early life predicts risk of islet autoimmunity in children with a first-degree relative with type 1 diabetes. Diabetes Care 32:94–99CrossRefPubMedPubMedCentral

47.

Barrett JC, Clayton DG, Concannon P et al (2009) Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 41:703–707CrossRefPubMedPubMedCentral

48.

Steck AK, Dong F, Wong R et al (2014) Improving prediction of type 1 diabetes by testing non-HLA genetic variants in addition to HLA markers. Pediatr Diabetes 15:355–362CrossRefPubMedPubMedCentral

49.

Barker JM, Goehrig SH, Barriga K et al (2004) Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care 27:1399–1404CrossRefPubMed

50.

Ziegler AG, Meier-Stiegen F, Winkler C, Bonifacio E (2012) Prospective evaluation of risk factors for the development of islet autoimmunity and type 1 diabetes during puberty--TEENDIAB: study design. Pediatr Diabetes 13:419–424CrossRefPubMed

Titel: The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants
verfasst von: Farah A. Meah
Linda A. DiMeglio
Carla J. Greenbaum
Janice S. Blum
Jay M. Sosenko
Alberto Pugliese
Susan Geyer
Ping Xu
Carmella Evans-Molina
for the Type 1 Diabetes TrialNet Study Group
Publikationsdatum: 19.03.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Diabetologia / Ausgabe 6/2016
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-016-3924-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

The fetal glucose steal: an underappreciated phenomenon in diabetic pregnancy

Bavachinin, as a novel natural pan-PPAR agonist, exhibits unique synergistic effects with synthetic PPAR-γ and PPAR-α agonists on carbohydrate and lipid metabolism in db/db and diet-induced obese mice

Gaps in life expectancy for people with type 1 diabetes

Egg consumption and risk of type 2 diabetes: a prospective study and dose–response meta-analysis

Risk of epilepsy in type 1 diabetes mellitus: a population-based cohort study

Cell-autonomous programming of rat adipose tissue insulin signalling proteins by maternal nutrition